Figure 3.

Discordance on metabolic and morphological imaging. Baseline and post Gefitinib axial CT (3a and d) and fused PET/CT (3b and e) images in soft tissue window show no interval change in size and metabolic activity of primary lung mass. Focal FDG uptake in the marrow of right pubic bone (3f – arrow) is a new finding However, axial CT - baseline and post-treatment images in bone window show no demonstrable lesion, thus patient has stable disease (SD) by RECIST. However, new hypermetabolic metastatic marrow lesion is suggestive of progressive metabolic disease (PMD) on EORTC criteria